A few recent studies revealed that EMPA ameliorated peripheral neuropathy in DM type 1 experimental models without mechanistic insights, though SGLT-2 inhibitors have not yet been approved for type 1 DM (Lee et al. 2018; Eid et al. 2020). The gene discussed is SLC5A2; the disease is peripheral neuropathy.